category,datetime,headline,id,image,related,source,summary,url
company,1768255264,44th Annual J.P. Morgan Healthcare Conference,138079901,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,BIIB,SeekingAlpha,2026-01-12. The following slide deck was published by Biogen Inc.,https://finnhub.io/api/news?id=c6fcbf3592f7e48f62ed1511d662bca600be590fc0eaf299288f31e2fbc18cbc
company,1768247158,Biogen Inc. (BIIB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript,138079428,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,BIIB,SeekingAlpha,Biogen Inc. (BIIB) 44th Annual J.P.,https://finnhub.io/api/news?id=e7565973c418970408885739a64f09be530dcd39b27c7302f5b7cc1756e27a56
company,1768237140,Biogen Inc. stock underperforms Monday when compared to competitors,138135953,,BIIB,MarketWatch,Biogen Inc. stock underperforms Monday when compared to competitors,https://finnhub.io/api/news?id=b511c07c921ab1d3a4fa17942431888062398eeeb46b4cb3f0745f3778e23b7d
company,1768233900,Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy,138075403,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BIIB,Yahoo,"Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and previously-treated nusinersen patients with SMA1Biogen is dedicated to partnering with the SMA community to advance care through scientific innovation and a commitment to enhancing outcomes for people living with SMA CAMBRIDGE, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the European Commission (EC) has granted ma",https://finnhub.io/api/news?id=0cfedb8c827b8ee9abf471c1045e84a023e1fcc576fb8a975034468468b6f474
company,1768216920,Biogen Gets European Approval of Higher-Dose Spinraza,138135954,,BIIB,MarketWatch,Biogen Gets European Approval of Higher-Dose Spinraza,https://finnhub.io/api/news?id=087f0f27dfa29c5cb58ba43d60e0114ca4a868ea7097e389234aed83112992d9
company,1768190718,3 Reasons to Sell BIIB and 1 Stock to Buy Instead,138072524,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BIIB,Yahoo,"The past six months have been a windfall for Biogen’s shareholders. The company’s stock price has jumped 41.7%, setting a new 52-week high of $188.65 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.",https://finnhub.io/api/news?id=f15fe0a0b4f1737ba2606bb36490a7fce84847a31dbcd2e541bb4a6f7e97af3d
